Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa-Reference-Cited by-同舟云学术

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

Published:2019-05-12 Issue:3 Volume:181 Page:609-611
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Prussick L.¹^ORCID,Rothstein B.¹,Joshipura D.¹,Saraiya A.²,Turkowski Y.³,Abdat R.¹,Alomran A.¹,Zancanaro P.¹,Kachuk C.¹,Dumont N.¹,Gottlieb A.B.⁴,Rosmarin D.¹

Affiliation:

1. Department of Dermatology Tufts Medical Center Boston MA U.S.A.

2. Department of Diagnostic Imaging Rhode Island Hospital The Warren Alpert Medical School of Brown University Providence, Rhode Island U.S.A.

3. Department of Dermatology VA Boston Healthcare System MA Center for Blistering Diseases Boston MA U.S.A.

4. Department of Dermatology Icahn School of Medicine at Mt. Sinai New York U.S.A.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.17822

Reference3 articles.